Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
Open Access
- 25 March 2011
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 16 (4), 497-511
- https://doi.org/10.1634/theoncologist.2010-0212
Abstract
Castleman's disease is a rare lymphoproliferative disorder in which there has been recent progress in elucidating underlying mechanisms with potential therapeutic implications. Unicentric Castleman's disease is an indolent condition that is often treated with local approaches. In contrast, patients with multicentric Castleman's disease (MCD) have a less favorable prognosis and require systemic treatment. Cytotoxic chemotherapy, with its attendant risk for toxicity, has been widely used to treat MCD, with variable efficacy. The discovery of putative etiologic factors and targets in MCD, particularly human herpes virus 8, CD20, and interleukin (IL)-6, has been translated into the use of rituximab and anti–IL-6-based therapy, as well as antiviral agents. In this article, we review the current state of the art of our understanding of Castleman's disease and its treatment and we provide insight into future treatment strategies based on disease biology.Keywords
Funding Information
- National Center for Research Resources (RR024148)
This publication has 118 references indexed in Scilit:
- Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)Molecular Cancer Therapeutics, 2010
- Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 ReceptorJournal of Virology, 2009
- Immunological and Inflammatory Functions of the Interleukin-1 FamilyAnnual Review of Immunology, 2009
- Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP ChemotherapyCancer Research and Treatment, 2009
- HIV/AIDS: Epidemiology, Pathophysiology, and Treatment of Kaposi Sarcoma–Associated Herpesvirus Disease: Kaposi Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman DiseaseClinical Infectious Diseases, 2008
- New approaches to the treatment of human herpesvirus 8‐associated diseaseReviews in Medical Virology, 2008
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaThe New England Journal of Medicine, 1999
- Interleukin 6 Induces the Expression of Vascular Endothelial Growth FactorJournal of Biological Chemistry, 1996
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.JCI Insight, 1990